血管内栓塞和阿托瓦斯塔丁治疗复发性慢性腹腔内血瘤
Enzhen Lv1, Xiaoli Xue, Zitao Xu
1Dezhou Seventh People's Hospital, Dongfeng Zhong Lu, Decheng, Dezhou, Shandong, China.
The Journal of craniofacial surgery
|July 3, 2024
概括
复发性慢性腹膜下血瘤的治疗具有挑战性. 最少侵入性中脑膜动脉栓塞显示出希望,阿托瓦斯塔丁可以通过帮助血液瘤吸收来改善早期恢复.
科学领域:
- 神经外科 神经外科
- 血管干预放射学 血管干预放射学
背景情况:
- 复发性慢性腹膜下血瘤 (CSDH) 是一个重大的临床挑战.
- 切除术虽然有效,但具有侵入性,并与相当大的患者创伤有关.
研究的目的:
- 评估中脑膜动脉内血管栓塞 (MMA) 作为中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉内血管栓塞 (MMA) 作为中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉中脑膜动脉.
- 研究术后口服阿托瓦斯塔丁在增强血瘤吸收和改善早期康复方面所带来的潜在益处.
主要方法:
- 进行了MMA的内血管栓塞,作为切除术的最小侵入性替代方案.
- 在一些患者中,实行了口服阿托瓦斯塔丁的术后管理.
主要成果:
- 中间脑膜动脉栓塞在治疗CSDH方面表现出有效性.
- 这种手术与低复发率有关.
- 阿托瓦斯塔丁在早期康复阶段显示出增强血液瘤吸收的潜力.
结论:
- 血管内MMA栓塞是CSDH治疗的有希望的,最小侵入性的选择,复发率低.
- 手术后的阿托瓦斯塔丁可能是一个有价值的辅助疗法,用于改善患者在早期康复期的结果.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
672
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
672
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
514
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
514
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
628
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
628